Orexo AB (publ) (ORXOF)

Orexo AB (publ) (ORXOF) Healthcare & Pipeline Overview

Orexo AB (publ) is a Swedish specialty pharmaceutical company operating in the United States, Europe, and the United Kingdom. It focuses on developing and commercializing pharmaceuticals for conditions like opioid dependence and breakthrough pain, alongside a growing portfolio of digital therapies for mental health and substance use disorders.

What Is the Investment Thesis for ORXOF?

Orexo AB (publ) presents a research profile centered on its dual approach to specialty pharmaceuticals and digital therapies, targeting significant medical needs in the US, Europe, and UK markets. A key value driver is its established product portfolio, including Zubsolv for opioid dependence, Abstral for breakthrough cancer pain, and Edluar for insomnia, which provide current revenue streams. The company's robust development pipeline, featuring candidates like OX124 (naloxone rescue), OX125 (nalmefene rescue), OX640 (allergic reactions), and OX338 (moderate to severe pain), alongside the OX-MPI program, represents potential future growth catalysts upon successful clinical development and regulatory approvals. Furthermore, Orexo's strategic expansion into digital therapies with deprexis (depression), vorvida (alcohol use disorder), and modia (opioid use disorder) positions it to capitalize on the growing market for tech-enabled healthcare solutions. However, the company currently operates with a significant negative profit margin of -101.1% and a negative gross margin of -75.6%, indicating substantial operational challenges and a need for improved profitability. Its market capitalization stands at $0.07 billion, reflecting its status as a smaller player in the healthcare sector. The beta of 0.87 suggests lower volatility compared to the broader market, but the absence of a dividend yield means returns are solely dependent on capital appreciation.

Based on FMP financials and quantitative analysis

ORXOF Key Highlights

• Market Capitalization: Orexo AB (publ) maintains a market capitalization of $101.87M, reflecting its valuation as a specialty pharmaceutical and digital therapy company.
• Profitability Challenges: The company reported a significant negative profit margin of -101.1%, indicating that expenses substantially exceed revenues, posing a challenge to overall profitability.
• Gross Margin Performance: Orexo's gross margin stands at -75.6%, suggesting that the cost of goods sold, relative to sales, is very high and requires strategic review.
• Market Volatility: With a Beta of 0.87, Orexo's stock exhibits lower volatility compared to the broader market, potentially appealing to investors seeking more stable equity exposure within the healthcare sector.
• Employee Base: The company operates with a workforce of 110 employees, supporting its research, development, and commercialization efforts across pharmaceuticals and digital therapies.

Who Are ORXOF's Competitors?

ORXOF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ORXOF's Key Strengths?

• Diversified product portfolio spanning specialty pharmaceuticals and digital therapies.
• Established commercial presence in key markets including the US, Europe, and UK.
• Pipeline of development-stage products addressing significant medical needs.
• Strategic focus on high-need therapeutic areas like opioid dependence and pain management.

What Are ORXOF's Weaknesses?

• Significant negative profit margin (-101.1%) and gross margin (-75.6%) indicating profitability challenges.
• Relatively small market capitalization ($0.07 billion) compared to larger pharmaceutical players.
• Reliance on successful development and commercialization of pipeline products.
• OTC market listing may impact liquidity and investor perception.

What Could Drive ORXOF Stock Higher?

• Successful advancement and regulatory approval of pipeline products such as OX124 (naloxone rescue) or OX338 (moderate to severe pain), potentially opening new market segments.
• Increased market penetration and adoption of Orexo's digital therapies, including deprexis for depression, vorvida for alcohol use disorder, and modia for opioid use disorder, driving revenue growth.
• Strategic partnerships or licensing agreements for existing products or pipeline assets, which could provide non-dilutive funding or expand market reach.
• Positive clinical trial results for the OX-MPI program targeting microvascular diseases, validating its therapeutic potential and attracting further investment.

What Are the Key Risks for ORXOF?

• Financial-distress signal — its Altman Z-Score of 1.42 sits in the distress zone (elevated bankruptcy risk).
• Persistent negative profit margin (-101.1%) and gross margin (-75.6%), indicating significant challenges in achieving profitability and sustainable operations.
• Regulatory setbacks or delays in the approval process for new pharmaceutical candidates or digital therapies, impacting time-to-market and development costs.
• Intense competition within both the specialty pharmaceutical market and the rapidly evolving digital therapeutics space, potentially limiting market share and pricing power.
• Challenges in securing adequate reimbursement and market access for new digital therapies, which may face skepticism from payers and healthcare systems.
• The inherent risks associated with an "OTC Other" market listing, including lower liquidity, reduced transparency, and potential difficulty in attracting institutional investment.

What Are the Growth Opportunities for ORXOF?

• Expansion of Opioid Dependence Treatment Market: The market for opioid dependence treatments, where Orexo's Zubsolv is a key product, continues to be significant globally, especially in the United States. Ongoing public health efforts to combat the opioid crisis ensure sustained demand for effective treatments. Orexo has the opportunity to expand Zubsolv's market penetration through strategic partnerships, enhanced patient access programs, and potentially new formulations or indications. The timeline for this growth is ongoing, driven by the persistent need for treatment options and Orexo's established commercial presence in this therapeutic area.
• Advancement of Pharmaceutical Development Pipeline: Orexo's robust pipeline, including OX124 for naloxone rescue, OX125 for nalmefene rescue, OX640 for allergic reactions, and OX338 for moderate to severe pain, represents substantial future growth potential. Successful progression through clinical trials and regulatory approvals for these novel medications could unlock new revenue streams and address unmet medical needs. The OX-MPI program for microvascular diseases also adds diversification. These opportunities are typically mid-to-long term, spanning several years, contingent on clinical trial outcomes and market acceptance.
• Growth in Digital Therapeutics Market: The market for digital therapies, encompassing solutions like Orexo's deprexis (depression), vorvida (alcohol use disorder), and modia (opioid use disorder), is experiencing rapid expansion. Increasing adoption of telehealth, favorable regulatory frameworks for digital health solutions, and a growing recognition of their efficacy present a significant opportunity. Orexo can leverage its existing platforms and expand its digital therapy portfolio to address a broader range of conditions, potentially reaching a wider patient base with lower commercialization costs compared to traditional drugs. This is an ongoing, near-to-mid-term growth area.
• Geographic Market Expansion and Penetration: Orexo currently commercializes products in the United States, Europe, and the United Kingdom. There is an ongoing opportunity to deepen market penetration within these existing regions by optimizing sales and marketing strategies, securing broader reimbursement coverage, and exploring new distribution channels. Furthermore, evaluating expansion into additional international markets where there is a high prevalence of conditions addressed by Orexo's products, particularly for opioid dependence and mental health disorders, could unlock new revenue streams over the mid-to-long term.
• Leveraging Specialty Product Focus: Orexo's focus on specialty areas like breakthrough pain in cancer patients (Abstral) and short-term insomnia (Edluar) allows it to target niche markets with specific, often high-value, medical needs. Continued innovation within these therapeutic areas, such as developing improved formulations or exploring new indications for existing products, could enhance market share and profitability. The ability to maintain a strong competitive position in these specialized segments, potentially through intellectual property protection and strong clinician relationships, provides a stable growth avenue over the mid-term.

What Opportunities Does ORXOF Have?

• Expansion of existing products into new indications or geographies.
• Successful clinical development and regulatory approval of pipeline assets (e.g., OX124, OX338).
• Growth in the digital therapeutics market and increased adoption of deprexis, vorvida, and modia.
• Potential for strategic partnerships or collaborations to accelerate development or market access.

What Threats Does ORXOF Face?

• Intense competition from established pharmaceutical companies and emerging digital health firms.
• Regulatory hurdles and potential delays in product approvals for both drugs and digital therapies.
• Market acceptance and reimbursement challenges for novel digital therapeutic solutions.
• Funding requirements for ongoing R&D and commercialization efforts given current profitability.

What Are ORXOF's Competitive Advantages?

• Proprietary sublingual formulations for certain pharmaceutical products, potentially offering differentiated delivery methods.
• Established commercial infrastructure and regulatory approvals for key products in the US, Europe, and UK markets.
• Diversified portfolio combining traditional specialty pharmaceuticals with innovative digital therapeutics.
• Focus on specific, high-need therapeutic areas such as opioid dependence and breakthrough pain.

What Does ORXOF Do?

Orexo AB (publ), incorporated in 1994 and headquartered in Uppsala, Sweden, has evolved into a specialty pharmaceutical company with a dual focus on traditional pharmaceuticals and innovative digital therapies. The company develops and commercializes its product portfolio across key markets including the United States, Europe, and the United Kingdom. Its established pharmaceutical offerings include Zubsolv tablets, a medication specifically formulated for the treatment of opioid dependence, addressing a significant public health challenge. Additionally, Orexo provides Abstral, designed to manage breakthrough pain in cancer patients, and Edluar, a treatment for short-term insomnia. These products represent Orexo's commitment to addressing specific, often underserved, medical needs. Beyond its commercialized products, Orexo maintains an active development pipeline aimed at future market opportunities. This pipeline features OX124, a medication intended for naloxone rescue, and OX125, a medication for nalmefene rescue, both critical in overdose situations. The company is also developing OX640 for allergic reactions and OX338, a sublingual tablet formulation of ketorolac, targeting moderate to severe pain. Furthermore, Orexo is advancing the OX-MPI program, which focuses on the treatment of microvascular diseases associated with chronic inflammatory conditions, indicating a broader therapeutic interest. In a strategic diversification, Orexo has significantly invested in digital therapies, recognizing the potential of technology in healthcare. Its digital health portfolio includes deprexis, a therapy designed for the treatment of mild to severe depression, offering a scalable solution for mental health support. Vorvida addresses alcohol use disorder, providing digital intervention for a prevalent condition, while modia is being developed for opioid use disorder, complementing its pharmaceutical efforts in this area. This blend of traditional pharmaceuticals and digital health solutions positions Orexo as a dynamic player in the specialty healthcare sector, leveraging diverse modalities to improve patient outcomes.

What Products and Services Does ORXOF Offer?

• Develops and commercializes Zubsolv tablets for opioid dependence treatment.
• Offers Abstral for the management of breakthrough pain in cancer patients.
• Provides Edluar for the treatment of short-term insomnia.
• Engages in the development of OX124 for naloxone rescue and OX125 for nalmefene rescue.
• Advances OX640 for allergic reactions and OX338 for moderate to severe pain.
• Researches the OX-MPI program for microvascular diseases in chronic inflammatory conditions.
• Develops and commercializes digital therapies including deprexis for depression.
• Offers vorvida, a digital therapy for alcohol use disorder.
• Develops modia, a digital therapy targeting opioid use disorder.

How Does ORXOF Make Money?

• Develops and commercializes proprietary pharmaceutical products for specialty medical conditions.
• Generates revenue from the sales of prescription medications like Zubsolv, Abstral, and Edluar in key markets.
• Invests in research and development to build a pipeline of new drug candidates for future commercialization.
• Develops and commercializes digital therapeutic solutions, expanding revenue streams beyond traditional pharmaceuticals.
• Operates across the United States, Europe, and the United Kingdom, leveraging regional commercial teams.

What Industry Does ORXOF Operate In?

Orexo AB (publ) operates within the "Drug Manufacturers - Specialty & Generic" industry, a segment of the broader Healthcare sector characterized by innovation, stringent regulatory oversight, and evolving patient needs. The company's positioning is unique due to its dual focus on specialty pharmaceuticals for conditions such as opioid dependence, breakthrough pain, and insomnia, alongside a strategic expansion into digital therapies for mental health and substance use disorders. This dual approach allows Orexo to address diverse market segments. The specialty pharmaceutical market is driven by the demand for targeted treatments for complex conditions, often commanding premium pricing, while the digital therapeutics market is experiencing rapid growth, fueled by technological advancements and increasing acceptance of remote healthcare solutions. Orexo's competitors include both traditional pharmaceutical companies developing similar drug classes and emerging digital health firms. Its ability to navigate complex regulatory pathways and effectively commercialize both drug and software-based solutions will be critical for its competitive standing in these dynamic markets.

Who Are ORXOF's Key Customers?

• Patients requiring treatment for opioid dependence, such as those prescribed Zubsolv.
• Cancer patients experiencing breakthrough pain, who are prescribed Abstral.
• Individuals seeking treatment for short-term insomnia, utilizing Edluar.
• Healthcare providers and clinicians who prescribe Orexo's pharmaceutical products.
• Patients seeking digital interventions for conditions like depression, alcohol use disorder, and opioid use disorder.

Company Profile

Orexo AB (publ) operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Uppsala, SE. The company is led by CEO Nikolaj Sorensen. ORXOF has traded publicly since 2013.

F-Score 4/9Financial Health

Orexo AB (publ)'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.42 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Return on assets is -40.6%, showing how much profit it generates from its asset base. Its free cash flow yield is 18.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.03 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -29.9%, the inverse of the P/E and a quick read on earnings relative to price.

ORXOF Valuation & Market Position

With a $101.87M market cap, Orexo AB (publ) sits in the micro-cap segment of the market. Relative to its peer group, ORXOF's quantitative score of 50/100 is below the peer average of 66/100.

FY2026 estForward Outlook

Wall Street analysts project Orexo AB (publ) revenue of about $25.9M for fiscal 2026, with EPS near $-8.98.

ORXOF Financials

ORXOF Latest News

ORXOF Analyst Consensus

ORXOF MoonshotScore

ORXOF Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources